Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Cyteir Therapeutics (NASDAQ: CYT) to Dissolve After Discontinuing Development of CYT-0851

Cyteir Announces Halt of CYT-0851 Development and Company Dissolution

Biotech firm Cyteir Therapeutics, Inc. (NASDAQ: CYT) announced today its decision to terminate all development activities related to CYT-0851, its investigational monocarboxylate transporter inhibitor. Following a strategic review, the Cyteir’s Board of Directors has deemed it in the best interest of shareholders to dissolve the company. This course of action involves an orderly wind-down of operations, liquidation of assets, and distribution of remaining cash to shareholders.

Phase 1 Study Results and Decision Factors

CYT-0851, tested in a Phase 1 combination study with capecitabine or gemcitabine for advanced ovarian cancer and other solid tumors, demonstrated durable responses but failed to meet Cyteir’s criteria for further clinical development. Given the high costs associated with identifying predictive biomarkers for potential beneficiaries of CYT-0851 treatment and the present financial and regulatory conditions, Cyteir found the continuation of CYT-0851 development to be unfeasible. The Company will still administer treatments to patients presently enrolled in the ongoing Phase 1 study until the dissolution takes effect.

Liquidation and Dissolution Plan

Cyteir’s Board of Directors will approve a Plan of Liquidation and Dissolution, given shareholder consent, that includes distributing remaining cash to shareholders after an orderly wind-down of the company’s operations. This plan includes the potential sale of its assets and the completion of all regulatory and patient obligations connected to the ongoing clinical trial. Cyteir will seek advisory services from independent consultants proficient in company dissolutions and liquidations.

A special shareholder meeting will be held in the latter half of 2023 to vote on the Plan of Dissolution. Shareholders will receive an estimate of potential distributions from Cyteir, though actual amounts may significantly differ due to various factors.

Termination of Cyteir Stock Trading

Once the certificate of dissolution is filed, trading of Cyteir’s common stock will cease, its stock transfer books will close, and transfers of its capital stock will no longer be recorded. The company will establish a reserve to pay for all expenses, obligations, and liabilities, with an expectation that its existing capital resources and anticipated net proceeds from the sale of certain assets will suffice to meet these costs.

Cyteir does not intend to make further comments on the planned liquidation and dissolution until a proxy statement related to the special meeting is filed with the SEC.

CYT: Market Response

Despite the news of a dissolution, shares of Cyteir are rallying 37.50% through early trading on June 30, 2023. Over the past three months, Cyteir shares have seen average daily volume of 41,870 shares. However, volume of 7.58 million shares or dollar volume of around $20.01 million, has already exchanged hands through early trading. On a year-to-date basis, Cyteir shares have returned nearly 62% through the first half of 2023.

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post Cyteir Therapeutics (NASDAQ: CYT) to Dissolve After Discontinuing Development of CYT-0851 appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.